Kindstar Globalgene Technology (HKG:9960) acquired a 49% equity interest in AnchorDx Inc. from AnchorDx Group HK.
The company settled the consideration for the acquisition by issuing 15,869,521 shares to WXHY Anchor Investment and 43,561,835 shares to OrbiMed Asia Partner at HK$1.42 apiece, a Friday Hong Kong bourse filing said.
Meanwhile Kindstar Global Medical Technology (Wuhan), a subsidiary of the company, also acquired 100% equity interest in Guangzhou Kangcheng Weiye Biotechnology from AnchorDx Group HK.
The group funded the acquisition consideration through internal resources and external funding.
After the completion, Guangzhou Kangcheng Weiye Biotechnology became a subsidiary of the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。